Hyundai Bioscience Balance Sheet Health
Financial Health criteria checks 4/6
Hyundai Bioscience has a total shareholder equity of ₩43.7B and total debt of ₩25.2B, which brings its debt-to-equity ratio to 57.6%. Its total assets and total liabilities are ₩71.0B and ₩27.2B respectively. Hyundai Bioscience's EBIT is ₩78.8M making its interest coverage ratio 0.1. It has cash and short-term investments of ₩8.1B.
Key information
57.6%
Debt to equity ratio
₩25.17b
Debt
| Interest coverage ratio | 0.08x |
| Cash | ₩8.06b |
| Equity | ₩43.74b |
| Total liabilities | ₩27.23b |
| Total assets | ₩70.97b |
Recent financial health updates
Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?
Nov 12
Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07
Recent updates
Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?
Nov 12The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Mar 14Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher
Jan 03The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Nov 29Financial Position Analysis
Short Term Liabilities: A048410's short term assets (₩9.1B) do not cover its short term liabilities (₩26.4B).
Long Term Liabilities: A048410's short term assets (₩9.1B) exceed its long term liabilities (₩790.5M).
Debt to Equity History and Analysis
Debt Level: A048410's net debt to equity ratio (39.1%) is considered satisfactory.
Reducing Debt: A048410's debt to equity ratio has increased from 27.4% to 57.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A048410 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A048410 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 18.5% per year.